Dose Reduction and Discontinuation With Anti-Fibrotic Medications

NCT05779007 · clinicaltrials.gov ↗

COMPLETED

Status

2778

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Pirfenidone
DRUG: Nintedanib

Sponsor

Boehringer Ingelheim